Search the Epitope Variant and Escape Mutation Database

Help

Found 2 matching records:

Displaying record number 52308

HXB2 Location Gag(77-85) Gag Epitope Map
View variants at this location

SLYNTVATL

`SLfNTVATL`		susceptible form
`SLYNTiATL`		susceptible form
`SLYNTVAvL`		susceptible form

Species (MHC/HLA) (A*02:01)

Variant Details

Showing all: 3 variant(s).

Variant ID.	`3244`
Epitope Seq.	`SLYNTVATL`
Variant Seq.	`SLfNTVATL`
Mutations	Y/F
Epitope Location	Y3F
HXB2 Location	Y79F
Mutation Type	SF: susceptible form
Note	SLfNTVATL was a recognized variant.

Variant ID.	`3245`
Epitope Seq.	`SLYNTVATL`
Variant Seq.	`SLYNTiATL`
Mutations	V/I
Epitope Location	V6I
HXB2 Location	V82I
Mutation Type	SF: susceptible form
Note	SLYNTiATL was a recognized variant.

Variant ID.	`3246`
Epitope Seq.	`SLYNTVATL`
Variant Seq.	`SLYNTVAvL`
Mutations	T/V
Epitope Location	T8V
HXB2 Location	T84V
Mutation Type	SF: susceptible form
Note	SLYNTVAvL was a recognized variant.

References

Schoenbach2002 Christian Schönbach, Yu Kun, and Vladimir Brusic. Large-scale Computational Identification of HIV T-Cell Epitopes. Immunol. Cell Biol., 80(3):300-306, Jun 2002. PubMed ID: 12067417. Show all entries for this paper.

Sewell1997 A. K. Sewell, G. C. Harcourt, P. J. Goulder, D. A. Price, and R. E. Phillips. Antagonism of Cytotoxic T Lymphocyte-Mediated Lysis by Natural HIV-1 Altered Peptide Ligands Requires Simultaneous Presentation of Agonist and Antagonist Peptides. Eur. J. Immunol., 27:2323-2329, 1997. PubMed ID: 9341776. Show all entries for this paper.

Displaying record number 85

HXB2 Location Gag(77-85) Gag Epitope Map
View variants at this location

Epitope

SLYNTVATL

Epitope Alignment

Variants

`SLfNTVATL`		observed variant
`SLfNTVAvL`		diminished HLA binding or increased off-rate
`SLsNTVATL`		diminished HLA binding or increased off-rate
`SsfNTVATL`		observed variant
`SLlNTVATL`		diminished HLA binding or increased off-rate
`SLcNTVATL`		diminished HLA binding or increased off-rate
`SLYNTiATL`		observed variant
`SLfNaVATL`		diminished HLA binding or increased off-rate
`SLfNTiAvL`		diminished HLA binding or increased off-rate
`SLfNTiATL`		observed variant
`SLYNTiAvL`		diminished HLA binding or increased off-rate

Epitope Name SL9

Species (MHC/HLA) human(A2)

Variant Details

Showing all: 11 variant(s).

Variant ID.	`3233`
Epitope Seq.	`SLYNTVATL`
Variant Seq.	`SLfNTVATL`
Mutations	Y/F
Epitope Location	Y3F
HXB2 Location	Y79F
Mutation Type	OV: observed variant
Method	Chromium-release assay, HLA binding
Note	Natural 3F variant SLfNTVATL, was found in patients 001 and 008. Variant peptide bound HLA-A*02 at a relative binding of 109% compared to SL9 index peptide. Lysis is abrogated in CTL line 9300868 at lower concentrations, but occurs in CTL line 003.

Variant ID.	`3234`
Epitope Seq.	`SLYNTVATL`
Variant Seq.	`SLfNTVAvL`
Mutations	Y/F T/V
Epitope Location	Y3F T8V
HXB2 Location	Y79F T84V
Mutation Type	DHB: diminished HLA binding or increased off-rate
Method	Chromium-release assay, HLA binding
Note	Natural 3F,8V variant SLfNTVAvL, was found in patients 001 and 008. Variant peptide bound HLA-A*02 at a relative binding of 72% compared to SL9 index peptide. Lysis is abrogated in CTL line 9300868 at lower concentrations, but occurs in CTL line 003.

Variant ID.	`3235`
Epitope Seq.	`SLYNTVATL`
Variant Seq.	`SLsNTVATL`
Mutations	Y/S
Epitope Location	Y3S
HXB2 Location	Y79S
Mutation Type	DHB: diminished HLA binding or increased off-rate
Method	Chromium-release assay, HLA binding
Note	Natural 3S variant SLsNTVATL, was found in patient 008. Variant peptide bound HLA-A*02 at a relative binding of 84% compared to SL9 index peptide. Lysis is abrogated in CTL lines 9300868 and 003 at lower concentrations.

Variant ID.	`3236`
Epitope Seq.	`SLYNTVATL`
Variant Seq.	`SsfNTVATL`
Mutations	L/S Y/F
Epitope Location	L2S Y3F
HXB2 Location	L78S Y79F
Mutation Type	OV: observed variant
Method	Chromium-release assay, HLA binding
Note	Natural 2S,3F variant SsfNTVATL, was found in patient 008.

Variant ID.	`3237`
Epitope Seq.	`SLYNTVATL`
Variant Seq.	`SLlNTVATL`
Mutations	Y/L
Epitope Location	Y3L
HXB2 Location	Y79L
Mutation Type	DHB: diminished HLA binding or increased off-rate
Method	Chromium-release assay, HLA binding
Note	Natural 3L variant SLlNTVATL, was found in patients 003 and 008. Variant peptide bound HLA-A*02 at a relative binding of 76% compared to SL9 index peptide. Lysis is abrogated in CTL lines 9300868 and 003 at lower concentrations.

Variant ID.	`3238`
Epitope Seq.	`SLYNTVATL`
Variant Seq.	`SLcNTVATL`
Mutations	Y/C
Epitope Location	Y3C
HXB2 Location	Y79C
Mutation Type	DHB: diminished HLA binding or increased off-rate
Method	Chromium-release assay, HLA binding
Note	Variant peptide SLcNTVATL bound HLA-A*02 at a relative binding of 86% compared to SL9 index peptide. Lysis is abrogated in CTL lines 9300868 and 003 at lower concentrations.

Variant ID.	`3239`
Epitope Seq.	`SLYNTVATL`
Variant Seq.	`SLYNTiATL`
Mutations	V/I
Epitope Location	V6I
HXB2 Location	V82I
Mutation Type	OV: observed variant
Method	Chromium-release assay, HLA binding
Note	Natural 6I variant SLYNTiATL, was found in patients 9300868 and 241. Variant peptide bound HLA-A*02 at a relative binding of 114% compared to SL9 index peptide. Lysis of CTL lines occurs at all concentrations of peptide tested.

Variant ID.	`3240`
Epitope Seq.	`SLYNTVATL`
Variant Seq.	`SLfNaVATL`
Mutations	Y/F T/A
Epitope Location	Y3F T5A
HXB2 Location	Y79F T81A
Mutation Type	DHB: diminished HLA binding or increased off-rate
Method	Chromium-release assay, HLA binding
Note	3F, 5A variant peptide SLfNaVATL bound HLA-A*02 at a relative binding of 80% compared to SL9 index peptide, but is a strict antagonist. Lysis is abrogated in CTL lines 9300868 and 003 at all concentrations tested.

Variant ID.	`3241`
Epitope Seq.	`SLYNTVATL`
Variant Seq.	`SLfNTiAvL`
Mutations	Y/F V/I T/V
Epitope Location	Y3F V6I T8V
HXB2 Location	Y79F V82I T84V
Mutation Type	DHB: diminished HLA binding or increased off-rate
Method	Chromium-release assay, HLA binding
Note	3F, 6I, 8V variant peptide SLfNTiAvL bound HLA-A*02 at a relative binding of 48% compared to SL9 index peptide. Lysis is abrogated in CTL line 9300868 but occurs in CTL line 003.

Variant ID.	`3242`
Epitope Seq.	`SLYNTVATL`
Variant Seq.	`SLfNTiATL`
Mutations	Y/F V/I
Epitope Location	Y3F V6I
HXB2 Location	Y79F V82I
Mutation Type	OV: observed variant
Method	Chromium-release assay, HLA binding
Note	3F, 6I variant peptide SLfNTiATL bound HLA-A*02 at a relative binding of 100% compared to SL9 index peptide. Lysis occurs in both CTL lines 9300868 and 003.

Variant ID.	`3243`
Epitope Seq.	`SLYNTVATL`
Variant Seq.	`SLYNTiAvL`
Mutations	V/I T/V
Epitope Location	V6I T8V
HXB2 Location	V82I T84V
Mutation Type	DHB: diminished HLA binding or increased off-rate
Method	Chromium-release assay, HLA binding
Note	6I, 8V variant peptide SLYNTiAvL was found in patient 9300868 and bound HLA-A*02 at a relative binding of 58% compared to SL9 index peptide. Lysis occurs in both CTL lines 9300868 and 003.